These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8467227)

  • 1. Karyotypic analysis in primary myelodysplastic syndromes.
    Noël P; Tefferi A; Pierre RV; Jenkins RB; Dewald GW
    Blood Rev; 1993 Mar; 7(1):10-8. PubMed ID: 8467227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Diagnosis and prognosis in myelodysplastic syndromes. The impact of cytogenetics].
    Mecucci C
    Recenti Prog Med; 2014 Mar; 105(3):110-4. PubMed ID: 24675452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical importance of interphase cytogenetics detecting occult chromosome lesions in myelodysplastic syndromes with normal karyotype.
    Rigolin GM; Bigoni R; Milani R; Cavazzini F; Roberti MG; Bardi A; Agostini P; Della Porta M; Tieghi A; Piva N; Cuneo A; Castoldi G
    Leukemia; 2001 Dec; 15(12):1841-7. PubMed ID: 11753603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantity of clonal cells detected by conventional cytogenetic analysis correlates with bone marrow blasts and survival in myelodysplastic syndromes.
    Kim M; Chung S; See CJ; Yoon SS; Kim BK; Kim HK; Lee DS
    Leuk Res; 2012 Feb; 36(2):163-8. PubMed ID: 21920602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitation of minimal residual disease in acute myelogenous leukemia and myelodysplastic syndromes in complete remission by molecular cytogenetics of progenitor cells.
    Engel H; Drach J; Keyhani A; Jiang S; Van NT; Kimmel M; Sanchez-Williams G; Goodacre A; Andreeff M
    Leukemia; 1999 Apr; 13(4):568-77. PubMed ID: 10214863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of risk groups in myelodysplastic syndromes. A multicenter study.
    Belli C; Acevedo S; Bengio R; Arrossagaray G; Watman N; Rossi N; García J; Flores G; Goldztein S; Larripa I
    Haematologica; 2002 Jan; 87(1):9-16. PubMed ID: 11801460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical relevance of cytogenetics in myelodysplastic syndromes.
    Bernasconi P; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Dambruoso I; Caresana M
    Ann N Y Acad Sci; 2006 Nov; 1089():395-410. PubMed ID: 17261783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromosome abnormalities in the myelodysplastic syndromes.
    Heim S; Mitelman F
    Clin Haematol; 1986 Nov; 15(4):1003-21. PubMed ID: 3552345
    [No Abstract]   [Full Text] [Related]  

  • 9. Hypoplastic myelodysplastic syndrome (h-MDS) is a distinctive clinical entity with poorer prognosis and frequent karyotypic and FISH abnormalities compared to aplastic anemia (AA).
    Koh Y; Lee HR; Song EY; Kim HK; Kim I; Park S; Park MH; Kim BK; Yoon SS; Lee DS
    Leuk Res; 2010 Oct; 34(10):1344-50. PubMed ID: 20427085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of clone size with a single cytogenetic abnormality on the revised International Prognostic Scoring System in myelodysplastic syndromes.
    Alkharabsheh O; Saadeh SS; Patnaik MS; Alkhateeb H; Gangat N; Begna KH; Hogan WJ; Greipp PT; He R; Nguyen PL; Litzow MR; Al-Kali A
    Am J Hematol; 2018 Dec; 93(12):E398-E401. PubMed ID: 30218541
    [No Abstract]   [Full Text] [Related]  

  • 11. A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q- syndrome from refractory anemia in primary myelodysplastic syndrome.
    Cermák J; Michalová K; Brezinová J; Zemanová Z
    Leuk Res; 2003 Mar; 27(3):221-9. PubMed ID: 12537974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow karyotype and prognosis in primary myelodysplastic syndromes.
    Billström R; Thiede T; Hansen S; Heim S; Kristoffersson U; Mandahl N; Mitelman F
    Eur J Haematol; 1988 Oct; 41(4):341-6. PubMed ID: 3197821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorescence in situ hybridization improves the detection of 5q31 deletion in myelodysplastic syndromes without cytogenetic evidence of 5q-.
    Mallo M; Arenillas L; Espinet B; Salido M; Hernández JM; Lumbreras E; del Rey M; Arranz E; Ramiro S; Font P; González O; Renedo M; Cervera J; Such E; Sanz GF; Luño E; Sanzo C; González M; Calasanz MJ; Mayans J; García-Ballesteros C; Amigo V; Collado R; Oliver I; Carbonell F; Bureo E; Insunza A; Yañez L; Muruzabal MJ; Gómez-Beltrán E; Andreu R; León P; Gómez V; Sanz A; Casasola N; Moreno E; Alegre A; Martín ML; Pedro C; Serrano S; Florensa L; Solé F
    Haematologica; 2008 Jul; 93(7):1001-8. PubMed ID: 18591625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cytogenetics of myelodysplastic syndromes.
    Olney HJ; Le Beau MM
    Best Pract Res Clin Haematol; 2001 Sep; 14(3):479-95. PubMed ID: 11640866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of clonal chromosomal abnormalities in patients with primary myelodysplastic syndromes.
    Gyger M; Infante-Rivard C; D'Angelo G; Forest L; Lussier P
    Am J Hematol; 1988 May; 28(1):13-20. PubMed ID: 3369432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine.
    Lübbert M; Wijermans P; Kunzmann R; Verhoef G; Bosly A; Ravoet C; Andre M; Ferrant A
    Br J Haematol; 2001 Aug; 114(2):349-57. PubMed ID: 11529854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural aberrations of chromosome 7 revealed by a combination of molecular cytogenetic techniques in myeloid malignancies.
    Brezinová J; Zemanová Z; Ransdorfová S; Pavlistová L; Babická L; Housková L; Melichercíková J; Sisková M; Cermák J; Michalová K
    Cancer Genet Cytogenet; 2007 Feb; 173(1):10-6. PubMed ID: 17284364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of cytogenetic subclasses and recurring chromosomal aberrations in AML and MDS with complex karyotypes using M-FISH.
    Van Limbergen H; Poppe B; Michaux L; Herens C; Brown J; Noens L; Berneman Z; De Bock R; De Paepe A; Speleman F
    Genes Chromosomes Cancer; 2002 Jan; 33(1):60-72. PubMed ID: 11746988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of hematologic diseases using conventional karyotyping, fluorescence in situ hybridization (FISH), and comparative genomic hybridization (CGH).
    Wilkens L; Tchinda J; Burkhardt D; Nolte M; Werner M; Georgii A
    Hum Pathol; 1998 Aug; 29(8):833-9. PubMed ID: 9712425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interphase cytogenetics of hematological cancer: comparison of classical karyotyping and in situ hybridization using a panel of eleven chromosome specific DNA probes.
    Poddighe PJ; Moesker O; Smeets D; Awwad BH; Ramaekers FC; Hopman AH
    Cancer Res; 1991 Apr; 51(7):1959-67. PubMed ID: 2004382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.